PLEKHA4

Across TCGA pan-cancer cohorts, PLEKHA4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLEKHA4 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLEKHA4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHA4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PLEKHA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.730	1.000	.016	5	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
GBM	DFS	Tertile	All	0.309	0.446	.045	2	view →
LSCC	DFS	Quartile	All	0.668	0.875	.037	1	view →
HNSC	OS	Quartile	II,III,IV	0.906	1.000	.018	1	view →
LUAD	DFS	Quartile	II,III,IV	0.812	0.968	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLEKHA4–CCRCC (OS)

Open the CCRCC breakdown →